ELAHERE was evaluated in the pivotal SORAYA trial, a single-arm study in 106 patients with platinum-resistant ovarian cancer whose tumours expressed high levels of FRα (also known as Folate ...
That drug – called mirvetuximab soravtansine – also had new data reported at ASCO from the phase 3 SORAYA trial, which involves patients with FRα-positive ovarian cancer who have previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback